The influence of neoadjuvant targeted therapy on the choice of surgical treatment of patients with localized renal cell carcinoma

Authors

  • О.A. Voylenko National Cancer Institute, Ukraine

DOI:

https://doi.org/10.26641/2307-5279.23.1.2019.161663

Keywords:

renal cell carcinoma, neoadjuvant targeted therapy

Abstract

Objective. To increase efficacy of localized RCC treatment by developing a combined approach using neoadjuvant targeted therapy (TT). Маterials and methods. Results of a randomized clinical study evaluating efficacy of neoadjuvant TT in patients with localized RCC. Main group consisted of 58 randomized patients who underwent 2 cycles of neoadjuvant TT, followed by an assessment of its efficacy and surgical treatment (renal resection or nephrectomy); control group included 60 randomized patients who received only surgical treatment. Results. Average tumor regression after TT was (M±SD (95% CI)) 20,5±14,3 (16.8–24,3)%. The size of RCC decreased in average by 12,3 mm, from (M±SD (95% CI)) 60,8±19,7 (55,7–66) to 48,5±16,4 (44,2±52, 8) mm (t-test; p<0,001). Tumor size reduction in the group of neoadjuvant TT allowed performing partial nephrectomy in 53 cases (91,4%), whereas in the control group, the number of nephron-sparing surgeries was only 20 (33,3%) (x2=42.1; p<0,0001). Neoadjuvant TT in patients with localized RCC leads to reliable regression of the tumor, which ensures the possibility of conducting organ-sparing surgical treatment in 91.4% of cases (x2=42.1; p<0.0001).

References

EAU Guidelines on Renal Cell Carcinoma 2018 ISBN/EAN: 978-94-92671-01-1. https://uroweb.org/guideline/renal-cell-carcinoma/.

NCCN Guidelines Version 2.2019. Kidney Cancer. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):333–42. DOI: 10.1161/CIRCOUTCOMES.113.000221.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296–305. DOI:10.1056/NEJMoa041031.

Herzog CA, Asinger RW, Berger AK, Charytan DM, Dнez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011 Sep;80(6):572–86. DOI: 10.1038/ki.2011.223.

Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron- sparing surgery. BJUInt2010;106:1270–6. DOI: 10.1111/j.1464-410X.2010.09357.

Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010 Sep; 184(3): 859–64. DOI: 10.1016/j.juro.2010.05.041.

Rini BI, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015;194:297–303. DOI: 10.1016/j.juro.2015.03.096.

Lane BR, Derweesh IH, Kim HL, O’Malley R, Klink J, Ercole CE, et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol 2015;33:112e15–e21. DOI: 10.1016/j.urolonc.2014.11.009.

Thomas A A , Rini B I, Lane B R , Garcia J , Dreicer R , Klein E A , et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009;181:518–23. DOI: 10.1016/j.juro.2008.10.001.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–47. DOI: 10.1016/j.ejca.2008.10.026.

Shuch B, Linehan WM, Bratslavsky G. Repeat partial nephrectomy: surgical, functional and oncological outcomes. Curr Opin Urol. 2011 Sep;21(5):368–75. DOI: 10.1097/MOU.0b013e32834964ea.

Стаховський Е. О., Войленко О. А., Вітрук Ю. В., Стаховський О. Е. / Застосування нефрометрії для вибору тактики лікування хворих з приводу нирковоклітинного раку // Клінічна хірургія. – 2015. – № 3. – С. 55–60. Stakhovskiy EO, Voylenko OA, Vitruk YV, Stakhovskiy OE. Application of nephrometry for choice of the treatment tactics in patients, suffering nephrocellular cancer Klin Khir. 2015 Mar;(3):55–60. [Article in Ukrainian] PMID: 26072547.

Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol. 2018 Jan;36(1):31–37. DOI: 10.1016/j.urolonc.2017.07.015.

Hutson TE, Thoreson GR, Figlin RA, Rini BI. The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book. 2016;35:113–7. DOI: 10.14694/EDBK_158892.

Harshman LC, Drake CG, Haas NB, Manola J, Puligandla M, Signoretti S, et al. Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. Kidney Cancer. 2017 Jul 26;1(1):31–40. DOI: 10.3233/KCA-170010.

Rini BI, Garcia J ,Elson P ,Wood L, Shah S, Stephenson A, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012 May;187(5):1548–54. DOI: 10.1016/j.juro.2011.12.075.

Zhang Y, Li Y, Deng J, Ji Z, Yu H, Li H. Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma. PLoS One. 2015 Feb 3;10(2):e0115896. DOI: 10.1371/journal.pone.0115896.

Cost NG, Delacroix SE Jr, Sleeper JP, Smith PJ, Youssef RF, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena cava tumort trombus. Eur Urol. 2011 Jun;59(6):912–8. DOI: 10.1016/j.eururo.2011.02.032.

Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced non metastatic clear cell renal cell carcinoma. Eur Urol. 2014 Nov;66(5):874–80. DOI: 10.1016/j.eururo.2014.01.035.

Published

2019-03-29

Issue

Section

Oncourology